An epigenetic mechanism by which tumors manage to hide from the body's immune defenses has just been described by an ...

Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 ...

FDA drug approvals are reshaping biotech stocks—track key decisions, FDA leadership turmoil, and volatility. Click for a look ...

The addition of an off-the-shelf pooled stem cell product to a single unit of umbilical cord blood conferred favorable ...

The colorful dots at the center are cytotoxic granules used to destroy infected or cancerous cells. Credit: F. Lemaitre @ ...

May is Melanoma Awareness Month and Intermountain Health is offering an exciting treatment program for Utahns with advanced ...

Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety.

T cells, which target infection and disease, can become more effective after a meal. The finding might help improve ...

A collaboration between the University of Geneva and Lausanne University Hospital has shown in new detail how the body's defenses fight back against malignant cells. Those defenses involve T ...

Ipsoprubart, a first-in-class SIRP-targeting therapy, expands into T cell malignancies alongside ongoing pivotal study in secondary hemophagocytic lymphohistiocytosis (sHLH) ...